drugset / Trial / NCT03748940
Study of LY3074828 in Healthy Participants
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of this study is to evaluate different concentrations and formulations of LY3074828 compared to placebo ("dummy drug"). The study will consist of 2 parts: Part A and Part B. Screening is required within 28 days prior to the start of each study part. For each participant in Part A and Part B, the total duration of the clinical trial will be approximately 16 weeks, including screening.
Timeline
- Start
- 2018-10-10
- Primary completion
- 2019-06-18
- Completion
- 2019-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY900021 | Unknown | — | Subcutaneous |
| Subject | Mirikizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.